CoChat

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index; 43 of the 99 sources its claims cite were checked for support.

GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity

Open access
Cooper, Mark E., van Raalte, Daniël H. · 2025 · Journal of Clinical Investigation

Abstract

Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being largely dependent on the induction of weight loss. In more recent years, the role of this peptide beyond metabolism has progressively been explored, including its impact on kidney physiology and kidney clinical outcomes in people with obesity with or without diabetes. Indeed, despite only modest expression of the GLP-1 receptor in the kidney, the renoprotective actions of GLP-1 and its receptor agonists have become an area of intensive investigation. This Review appraises the current status of GLP-1 peptide and its receptor agonists and focuses on the preclinical as well as recent seminal clinical findings defining the kidney benefits conferred by GLP-1 receptor agonist treatment in people living with type 2 diabetes and obesity.

Overview

CoChat Summary

## TL;DR

This review summarizes evidence that GLP-1 receptor agonists have kidney benefits in type 2 diabetes and obesity, with effects seen in albuminuria, eGFR decline, and hard kidney outcomes. It also reviews proposed mechanisms and notes that benefits may be partly indirect through improvements in glycemia, weight, blood pressure, and cardiovascular function.

## Key findings

  • In cardiovascular outcome trials, GLP-1 receptor agonists consistently reduced urinary albumin-to-creatinine ratios by 20%–40% and reduced new-onset macroalbuminuria in people with T2D.
  • In the dedicated FLOW trial, 3,533 participants with T2D and CKD were randomized to semaglutide 1.0 mg weekly or placebo; semaglutide lowered the risk of the primary composite kidney outcome by 24%, the kidney-specific components by 21%, and reduced annual eGFR decline by 1.16 mL/min/1.73 m² versus placebo.
  • In SELECT, among participants without diabetes, semaglutide reduced the composite kidney endpoint by 22%; at 104 weeks, eGFR declined less with semaglutide (–0.86 mL/min/1.73 m²) than with placebo (–1.61 mL/min/1.73 m²).
  • In SMART, semaglutide 2.4 mg weekly reduced UACR by 52% at 24 weeks in people with overweight/obesity and non-diabetic CKD; a post hoc analysis of SURMOUNT-1 also found tirzepatide reduced UACR in overweight/obese people without T2D.

## Methods

  • This is a Review article that appraises preclinical, human physiology, and clinical trial evidence on GLP-1 receptor agonists and kidney outcomes in T2D and obesity.
  • The evidence base includes CVOTs, the FLOW kidney outcome trial, obesity/CKD trials such as SELECT and SMART, and mechanistic studies using kidney biopsy, single-cell sequencing, and multiparametric MRI.
  • The article synthesizes findings from randomized trials, post hoc and prespecified secondary analyses, and preclinical/physiologic studies rather than presenting original study data.

## Limitations

  • The review states that earlier CVOT kidney analyses did not specifically include patients with kidney disease, and the number of hard kidney outcomes was too low to make definitive conclusions.
  • It notes that the GLP-1 receptor is only modestly expressed in the kidney, and the precise mechanism of kidney benefit remains uncertain.
  • Evident from the text: several mechanistic conclusions are based on heterogeneous studies with inconsistent results across human physiology experiments, and some cited findings are post hoc or from secondary endpoints rather than primary kidney-outcome trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci194749

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 CKD drivers potentially affected by GLP-1 receptor agonist treatment. Several drivers of CKD may be impacted by GLP-1 receptor agonist treatment. Some of these effects may be related to direct kidney effects (A), while others may be due to effects of GLP-1 receptor agonists on kidney risk factors (B).
Figure 1 CKD drivers potentially affected by GLP-1 receptor agonist treatment. Several drivers of CKD may be impacted by GLP-1 receptor agonist treatment. Some of these effects may be related to direct kidney effects (A), while others may be due to effects of GLP-1 receptor agonists on kidney risk factors (B).CC BY · PubMed Central

Verification

Claims the paper makes

39 Valid · 0 Not valid · 46 Not checked · 28 Own results and interpretations

79 more claims · 22 with their cited sources checked

Create a free account to see all 113 claims and to verify the 12 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Citations

Cites

Show all 90 references

Research works printed but not linked: 3

  1. Cherney, Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease, Nephrol Dial Transplant
  2. Brown, 1970, Cleavage of a gastric inhibitory polypeptide with cyanogen bromide and the physiological action of the C-terminal fragment, J Physiol, 210, 52
  3. Rosenstock, Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes, N Engl J Med

Cited by

See all 24

Metadata

Authors
Cooper, M. E., & van Raalte, D. H.
Affiliations
  • Monash University (AU)
  • Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.
Corresponding author
Cooper, Mark E.
Venue
Journal of Clinical Investigation
Published
2025-11-03
Volume
135
Issue
21
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4415854994
Cited by
24
References
90
Citations by year
2026: 24
FWCI
3.24
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Eli Lilly and Company
  • AstraZeneca
  • Monash University
  • Nierstichting
  • Ministerio de Economía y Competitividad
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
GLP-1 receptor agonists, glucagon-like peptide-1, chronic kidney disease, type 2 diabetes, obesity, renal protection, renal function, insulin resistance, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Obesity, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. https://app.cochat.ai/papers/10.1172/jci194749
The paper
Cooper, M. E., & van Raalte, D. H. (2025). GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. Journal of Clinical Investigation. https://doi.org/10.1172/jci194749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.